Mylan is the worst-performing stock in the 61-member S&P 500 health-care index over the past 12 months with a 39 percent slump. Perrigo Co., another maker of generics, saw the second-biggest decline at 32 percent, while the …
Meanwhile, the stock's short-term options pits are decidedly put-skewed. Specifically, ALR sports a top-heavy Schaeffer's put/call open interest ratio (SOIR) of 3.61, which ranks in the 74th percentile of its annual range. MYL's strong earnings …
The resignation should have driven the stock lower, but as you can see from this chart it went up: By amazing coincidence, Mylan held a meeting for a select group of analysts -- including folks from UBS and Goldman Sachs-- the day after …
Pharma giant Mylan has agreed to pay the federal government $465 million to settle questions of how the company’s EpiPen was classified under the Medicaid Drug Rebate Program. Mylan announced the deal late on Friday afternoon. …
U.S. regulators have begun investigating possible manufacturing violations by Mylan Inc , the world's third-biggest generic drugmaker. Shares of Mylan fell 13 percent on Monday after a newspaper raised potential quality-control problems at a …
PITTSBURGH, Pa. - The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. Mylan said Monday that the deal will diversify and expand its business …
In the Nifty50 pack, 21 stocks were trading in the green, while 30 stocks were in red.less The stock cracked 6.96 per cent to hit a low of Rs 2,069.10 on BSE. The stock cracked 6.96 per cent to hit a low of Rs 2,069.10 on BSE.less In the …
It noted that the company's market capitalization has swelled to more than $20 billion from about $3 billion over the past 15 years, and its stock price also has soared over the longer time frame. "During Mr. Coury's long tenure, Mylan has …